Orforglipron (6mg) Dosage Protocol
Oral small-molecule GLP-1 receptor agonist — the active ingredient in FDA-approved Foundayo (2026); research-grade material for laboratory use only.
Quickstart Highlights
Orforglipron is an oral, small-molecule GLP-1 receptor agonist (Eli Lilly LY3502970) — a non-peptide that activates the same GLP-1 pathway as injectable agonists to curb appetite and support glucose control[1] — and has been studied for substantial weight loss and metabolic improvement in the phase 3 ATTAIN (obesity) and ACHIEVE (type 2 diabetes) programs[2][3]. Its non-peptide structure gives oral stability, so it is swallowed once daily with no injection and no strict food or water timing, while gradual 4-week titration keeps tolerability high[1][4]. Orforglipron is now FDA-approved as Foundayo™ (2026) for obesity, though the research-grade material here is not the approved product.
Swallow one or more 6 mg capsules once daily — ready to take, with no mixing or preparation.
6–36 mg once daily (gradual escalation over 12+ weeks in 4-week steps).
Each capsule is 6 mg, so 12 mg = two capsules, 24 mg = four, 36 mg = six. Taken by mouth, with or without food.
Keep capsules in their sealed bottle at room temperature, dry and out of direct light; no refrigeration or freezing required.
Important: Orforglipron is an oral capsule — there is nothing to mix or inject. This page is provided strictly for research and educational use only.
Oral Dosing Guide
Once-daily oral capsules and accurate step-up dosing, step by step
Standard / Gradual Titration Approach (6 mg oral capsules)
Oral administration — no mixing required: Orforglipron ships as ready-to-take 6 mg capsules. Simply swallow the day’s capsule count whole with water — there is no mixing and no preparation.
Typical daily range: 6–36 mg once daily (gradual escalation over 12+ weeks in 4-week steps).
Easy counting: Each capsule is 6 mg, so 12 mg = two 6 mg capsules, 24 mg = four, and 36 mg = six capsules.
Storage: Keep capsules in their sealed bottle at room temperature, dry and away from direct light; no refrigeration or freezing needed.
Frequency: one oral dose each day, taken by mouth with or without food. This schedule approximates the phase 3 escalation — the pivotal ATTAIN and ACHIEVE trials used once-daily doses of 3 mg, 12 mg and 36 mg with 4-week titration steps starting at 3 mg; the table above mirrors that escalation using the 6 mg product[2]. Stepping up gradually rather than starting high markedly softens early gastrointestinal effects[1][4].
How To Take
Count out the capsules for your current phase (for example, two 6 mg capsules for a 12 mg day).
Swallow them whole with a glass of water — with or without food, since there are no strict timing restrictions.
Take it at roughly the same time each day to keep exposure steady between doses.
Re-seal the bottle and store it at room temperature, dry and shielded from light.
Every dose in this protocol is a whole number of 6 mg capsules (1, 2, 4 or 6), so no splitting, crushing or measuring is required — just count the capsules for the current phase.
Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.
Supplies Needed
Quantities below assume a 12–24 week course of once-daily oral capsules, titrated gradually up to the maintenance dose. Each bottle holds 90 × 6 mg capsules.
Bottle use scales with the daily titration schedule (90 capsules per bottle).
- Weeks 1–4 at 6 mg/day (1 cap): 28 caps → ~1 bottle
- 12 weeks through 24 mg/day: ~476 caps → ~6 bottles
- 24 weeks incl. 36 mg maintenance: ~980 caps → ~11 bottles
- 6 mg/day: 1 bottle lasts ~90 days
- 12 mg/day (2 caps): 1 bottle lasts ~45 days
- 24 mg/day (4 caps): 1 bottle lasts ~22 days
- 36 mg/day (6 caps): 1 bottle lasts ~15 days
Helps keep once-daily capsule counts consistent across the week.
- 7-day organizer: pre-count each day’s capsules
- Reduces missed or double doses during titration
No refrigeration, mixing water or injection supplies are needed for oral capsules.
- Keep the sealed bottle at room temperature
- Store away from moisture and direct light
Protocol Overview
The once-daily oral regimen at a glance, drawn from the phase 3 trial protocols.
- ▪Goal: Drive meaningful weight loss (~11% of body weight over 72 weeks in ATTAIN-1) and stronger metabolic markers through GLP-1 receptor agonism[2][5].
- ▪Schedule: One oral capsule dose a day for 12+ weeks, with the dose raised gradually in 4-week steps.
- ▪Dose Range: 6–36 mg once daily; up to 36 mg is the highest maintenance dose in this schedule (trials evaluated up to 36 mg once daily)[1][3].
- ▪Preparation: None — capsules are ready to take. Each is 6 mg, so a target dose is simply a count of capsules (2 for 12 mg, 4 for 24 mg, 6 for 36 mg).
- ▪Storage: Keep the capsule bottle at room temperature, dry and out of direct light; no refrigeration required.
Dosing Protocol
The week-by-week titration, mapped to the phase 3 dosing.
- ▪Start: 6 mg once daily (one capsule) for the first 4 weeks to settle tolerability[1][4].
- ▪Escalation: Step up to 12 mg (two capsules) for Weeks 5–8, then 24 mg (four capsules) for Weeks 9–12[1].
- ▪Maintenance: Up to 36 mg once daily (six capsules) from Week 13 as tolerated; 24 mg is a reasonable step-down if side effects arise[2].
- ▪Frequency: Once a day, by mouth — holding the same time each day aids consistency.
- ▪Cycle Length: Roughly 12–16 weeks to finish escalation; trials ran to 72 weeks with continued, progressive weight loss[2].
- ▪Timing: Any steady daily schedule works; take with or without food.
Storage Instructions
Correct storage is what preserves the capsules’ stability and potency.
- ▪Capsules: Keep at room temperature in the sealed bottle for everyday use; shield from moisture and light[11][12].
- ▪No refrigeration: Unlike lyophilized peptides, oral capsules do not need to be frozen or chilled and require no mixing before use[11].
- ▪Handling: Keep the desiccant in the bottle, close the cap fully after each use, and keep capsules clear of heat, humidity and direct sun.
- ▪Shelf life: Use within the manufacturer’s labeled date; do not use capsules that are cracked, discolored or past expiry[12].
Important Notes
Practical points that keep once-daily oral dosing safe and consistent.
- ▪Daily consistency: Lock in one time of day for the capsule dose and keep to it for the whole protocol.
- ▪Gradual titration is essential: Starting at 6 mg once daily and stepping up in 4-week intervals markedly lowers the odds of early gastrointestinal effects[4].
- ▪Count, don’t split: Take whole capsules only — do not crush, open or split them; each 6 mg capsule is one unit of the dose.
- ▪No food or water timing rules: Unlike oral peptide GLP-1 tablets that require a fasting window, orforglipron’s non-peptide structure means it can be taken with or without food and without a fasting window[5].
- ▪Missed dose: If a day is missed, resume the usual once-daily count the next day; do not double up capsules to catch up.
- ▪Side-effect monitoring: Mild nausea or stomach upset is common while escalating; if it becomes notable, hold the current capsule count longer before stepping up.
How This Works
Orforglipron is an oral, small-molecule (non-peptide) GLP-1 receptor agonist: it activates the GLP-1 (glucagon-like peptide-1) receptor — the same pathway used by injectable GLP-1 agonists — to help regulate appetite, satiety and glucose-dependent insulin release[1][5]. These receptor actions reduce appetite and energy intake, slow gastric emptying, and improve glucose regulation, which together drive steady weight loss.
Because it is a non-peptide small molecule, orforglipron is orally bioavailable and stable in the gut, so it can be swallowed once daily with no injection and no strict food or water timing — a practical contrast to peptide GLP-1 agonists that require injection or a fasted oral tablet[5][8].
Its pharmacokinetics support a single daily dose that holds exposure steady between doses, with gradual 4-week titration to manage tolerability[1].
In the phase 3 ATTAIN-1 obesity trial (n=3,127 adults, 72 weeks), orforglipron produced about 11.2% mean weight loss[2]. In the ACHIEVE-1 program in type 2 diabetes, once-daily orforglipron produced meaningful A1c reductions[3].
These 2025 trials used once-daily doses of 3 mg, 12 mg and 36 mg with 4-week titration steps starting at 3 mg. Orforglipron is now FDA-approved as Foundayo™ (April 2026) for obesity, though this research-grade material is not the approved product; the supplier labels it research-use-only and not for human consumption[6][7].
Lifestyle Factors
Habits that work alongside the protocol to protect results and ease the transition.
- ▪Nutrition: Eat a balanced, protein-forward diet (1.0–1.2 g/kg body weight) to hold on to lean mass while losing weight[10].
- ▪Hydration: Keep fluids up, particularly while titrating, when GI effects peak.
- ▪Physical activity: Pair resistance training (2–3×/week) with moderate cardio to aid metabolic adaptation and protect muscle.
- ▪Sleep & stress: Aim for 7–9 hours of solid sleep and manage stress to support hormonal balance and stay on track.
- ▪Meal timing: Smaller, more frequent meals help some people handle GI effects during early titration.
Potential Benefits & Side Effects
What the phase 3 ATTAIN and ACHIEVE trials have reported (pre-approval phase 3 evidence).
Potential Benefits
- ▪Substantial weight loss: About 11.2% mean body-weight reduction by 72 weeks in ATTAIN-1[2].
- ▪Glycemic improvement: Meaningful A1c reductions in adults with type 2 diabetes in ACHIEVE-1[3].
- ▪Metabolic benefits: GLP-1 receptor agonism is associated with gains in appetite control and cardiometabolic risk markers[1][5].
- ▪Convenient oral dosing: A single daily capsule with no injection and no strict food or water timing is easier to stick with[1].
Common Side Effects
- ▪Gastrointestinal effects: Nausea, diarrhea, vomiting and constipation top the list of adverse events; usually mild-to-moderate and easing with time[2][4].
- ▪Slow titration helps: Starting at a low daily dose and stepping up every 4 weeks sharply cuts early GI events[4].
- ▪No injection-site reactions: Because it is taken orally, there are no needle sites, bruising or skin reactions to manage.
- ▪Regulatory status: Orforglipron is FDA-approved as Foundayo™ (2026) for obesity; long-term post-marketing safety continues to be characterized, and this research-grade material is not the approved product and is labeled research-use-only[6][7].
Oral Administration
Orforglipron is taken by mouth once daily — there is no mixing, no needle and no injection technique to learn. The steps below keep once-daily oral dosing simple and consistent[13][14].
Before You Dose
- ▪Wash your hands and confirm the capsule count for your current phase (1, 2, 4 or 6 capsules)[14].
- ▪Open the bottle, count out the day’s capsules, and re-seal the bottle right away to keep the desiccant working.
- ▪Have a glass of water ready. Food is optional — there is no fasting window required[13].
- ▪Inspect the capsules; do not use any that are cracked, discolored or past their expiry date.
Taking The Dose
- ▪Place the capsules on your tongue and swallow them whole with water[15].
- ▪Do not crush, chew, open or split the capsules — take each 6 mg capsule whole[13][14].
- ▪Take the full daily count in a single sitting; there is no need to space capsules across the day[13].
- ▪Aim for roughly the same time each day so exposure stays steady between doses.
After Your Dose
- ▪Close the bottle fully and return it to room-temperature storage away from moisture and light[14].
- ▪Log the dose (a 7-day pill organizer makes this easy) to avoid missed or double doses during titration.
- ▪If you miss a day, resume your usual once-daily count the next day — do not double up[15].
- ▪Watch for GI symptoms while escalating; hold the current capsule count longer if needed before stepping up.
Recommended Source
For high-purity Orforglipron (6 mg oral capsules, 90 per bottle), we point researchers to Prime Lab Peptides.
Why Prime Lab Peptides?
- ▪Top-rated on Trustpilot: Independently reviewed as the highest-rated peptide lab on Trustpilot — making it the best current source in the USA.
- ▪Third-party tested: Every batch ships with a Certificate of Analysis (COA) confirming purity and composition.
- ▪Consistent quality: ISO-aligned manufacturing and handling keep product integrity reliable batch to batch.
- ▪Convenient oral format: Ready-to-take 6 mg capsules — no mixing, water or injection supplies required.
- ▪Research-grade purity: Fit for educational and research use that demands high-quality material.
Note: Product availability and specifications subject to change. Orforglipron is FDA-approved as Foundayo™ for obesity; this research-grade material is labeled research-use-only / not for human consumption. Verify current product details on supplier website.
References
-
1
New England Journal of Medicine (2025)Orforglipron, an oral small-molecule GLP-1 receptor agonist: phase 3 design and dosing overview
-
2
Eli Lilly / ATTAIN-1 (2025)ATTAIN-1 obesity trial: once-daily oral orforglipron produced ~11.2% mean weight loss over 72 weeks (n=3,127)
-
3
Eli Lilly / ACHIEVE-1 (2025)ACHIEVE-1 type 2 diabetes trial: once-daily oral orforglipron produced meaningful A1c reductions
-
4
PubMed / Phase 3 program (2025)Orforglipron dosing and tolerability: gradual 4-week titration reduces gastrointestinal adverse events
-
5
Nature Reviews / Metabolism (2025)Oral small-molecule GLP-1 receptor agonists: mechanism, oral bioavailability and clinical landscape
-
6
Eli Lilly (2025)Orforglipron (LY3502970) regulatory status: FDA-approved as Foundayo (2026); research-grade product overview
-
7
PubMed (2025)Meta-analysis of GLP-1 receptor agonists for weight management: efficacy and adverse-event profile
-
8
Cell Metabolism (2024)Non-peptide GLP-1 receptor agonism: pharmacology of orally bioavailable small molecules
-
9
Nature Reviews Endocrinology (2024)GLP-1 receptor agonists for obesity and diabetes: a clinical landscape review
-
10
Journal of Cachexia, Sarcopenia and Muscle (PMC)Protein requirements during weight loss: preserving lean mass
-
11
USP / General ChaptersStorage and handling of oral solid dosage forms (capsules): temperature, humidity and light
-
12
FDAGuidance on storage of oral capsules and tablets (controlled room temperature, protect from moisture and light)
-
13
NCBI BookshelfOral medication administration best practices (swallowing whole, adherence and timing)
-
14
World Health OrganizationAdherence to long-term therapies: evidence for once-daily oral dosing and organizers
-
15
PubMed / Pharmacokinetics (2025)Once-daily oral GLP-1 receptor agonist dosing: exposure, half-life and titration considerations
-
16
Prime Lab PeptidesOrforglipron (6 mg, 90 capsules) product page (quality documentation and specifications)
How to take Orforglipron
- 1Confirm the capsule strength and your target dose from the schedule on this page (each capsule is a fixed strength).
- 2Take the required number of Orforglipron capsules by mouth once daily, swallowed whole with water, with or without food.
- 3Keep the daily dose consistent and follow any documented gradual 4-week escalation steps.
- 4Store the capsules sealed at room temperature, dry and away from light — no mixing or refrigeration needed.
Orforglipron — frequently asked questions
How is Orforglipron taken?
Orforglipron is taken by mouth as one or more capsules once daily, swallowed whole with or without food. There is no mixing, reconstitution, or injection — it is an oral small-molecule compound, not an injectable peptide.
Do I need bacteriostatic water or syringes for Orforglipron?
No. Because Orforglipron is an oral capsule, none of the injectable-peptide supplies (bacteriostatic water, insulin syringes, alcohol swabs) apply — you simply take the capsule(s) by mouth.
How many capsules make up each dose?
Each capsule is a fixed strength, so a dose is reached by taking the matching number of capsules — for example a 12 mg dose is two 6 mg capsules. The dosing table on this page lists the capsule count for each step of a documented research schedule.
How should I store Orforglipron?
Keep the capsules in their original sealed container at controlled room temperature, dry and away from heat, light and moisture, and follow the specific storage guidance supplied with your product. No refrigeration or reconstitution is required.
How does Orforglipron differ from injectable GLP-1 compounds?
Orforglipron activates the same GLP-1 receptor pathway as injectable GLP-1 agonists, but as an orally-available small molecule it is swallowed rather than injected and needs no reconstitution — the key practical difference researchers note.
Is the research-grade Orforglipron sold here approved for human use?
No. Research-grade Orforglipron is supplied strictly for laboratory and research purposes and is not an approved medicine for human use — regardless of whether an approved pharmaceutical product containing this ingredient exists. Everything here is research information, not medical advice; consult a licensed healthcare professional and the approved product labeling before any use.
New protocols & dosing updates
Reconstitution charts, new peptide protocols and safety updates — straight to your inbox. No spam, unsubscribe anytime.